3 Cancer Stocks to Watch in December

The American Society of Hematology (ASH) begins its 60th annual meeting on Dec. 1, and this year's going to be one to remember. Acceleron Pharma Inc. (NASDAQ:XLRN), bluebird bio (NASDAQ:BLUE), and Amgen Inc. (NASDAQ:AMGN) are all scheduled to present highly anticipated results from experimental cancer therapies that could be worth billions. Here's what investors need to watch out for.